Misplaced Pages

Enzomenib

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by Boghog (talk | contribs) at 04:02, 6 January 2025 (created drug stub). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 04:02, 6 January 2025 by Boghog (talk | contribs) (created drug stub)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)

Pharmaceutical compound
Enzomenib
Clinical data
Other namesDSP-5336
Identifiers
IUPAC name
  • 5-fluoro-2-octane-3-carbonyl]-2,7-diazaspirononan-2-yl]pyrimidin-5-yl]oxy-N,N-di(propan-2-yl)benzamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC33H43FN6O3
Molar mass590.744 g·mol
3D model (JSmol)
SMILES
  • CC(C)N(C(C)C)C(=O)C1=C(C=CC(=C1)F)OC2=CN=CN=C2N3CC4(C3)CCN(CC4)C(=O)56CC(N5)CC6=C
InChI
  • InChI=InChI=1S/C33H43FN6O3/c1-20(2)40(21(3)4)31(41)26-15-23(34)6-9-27(26)43-28-16-35-19-36-30(28)39-17-33(18-39)10-12-38(13-11-33)32(42)29-25-8-7-24(37-29)14-22(25)5/h6,9,15-16,19-21,24-25,29,37H,5,7-8,10-14,17-18H2,1-4H3/t24-,25+,29-/m0/s1
  • Key:JQHJEDMMWUIYCE-FVVBACEJSA-N

Enzomenib is an investigational new drug that is being evaluated for the treatment of acute leukemia. It is a small molecule inhibitor that targets the interaction between menin and mixed-lineage leukemia (MLL) proteins. Enzomenib particularly in patients with KMT2A (MLL) rearrangements or NPM1 mutations.

The U.S. Food and Drug Administration (FDA) has granted both Fast Track and Orphan Drug designations to Enzomenib.

References

  1. "Enzomenib - Sumitomo Pharma". AdisInsight. Springer Nature Switzerland AG.
  2. Dempke WC, Desole M, Chiusolo P, Sica S, Schmidt-Hieber M (September 2023). "Targeting the undruggable: menin inhibitors ante portas". Journal of Cancer Research and Clinical Oncology. 149 (11): 9451–9459. doi:10.1007/s00432-023-04752-9. PMID 37103568.
  3. "Sumitomo Pharma Presents New Clinical Data on DSP-5336 at the European Hematology Association 2024 Congress". Sumitomo Pharma Co., Ltd. 14 June 2024.
  4. Flaherty C (15 July 2024). "FDA Grants Fast Track Designation to DSP-5336 in KMT2A/NMP1+ AML". OncLive.
Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: